(-0.07%) 5 474.75 points
(-0.11%) 38 776 points
(-0.04%) 19 914 points
(0.20%) $80.49
(1.26%) $2.82
(0.25%) $2 334.90
(-0.16%) $29.35
(-0.22%) $968.80
(0.01%) $0.932
(-0.17%) $10.64
(0.06%) $0.788
(-1.87%) $86.79
Live Chart Being Loaded With Signals
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally...
Stats | |
---|---|
Šios dienos apimtis | 2.16M |
Vidutinė apimtis | 2.09M |
Rinkos kapitalizacija | 959.04M |
EPS | $-0.0913 ( Q1 | 2024-05-09 ) |
Kita pelno data | ( $0 ) 2024-08-05 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-7.29 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0110 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-28 | Gtcr Investment Xi Llc | Sell | 8 409 946 | Class B common stock |
2024-05-28 | Gtcr Investment Xi Llc | Sell | 8 409 946 | Common Units |
2024-05-28 | Gtcr Investment Xi Llc | Buy | 8 409 946 | Class A common stock |
2024-05-28 | Gtcr Investment Xi Llc | Sell | 9 940 974 | Class A common stock |
2024-05-23 | Mihas Constantine S | Buy | 20 645 | Class A Common Stock |
INSIDER POWER |
---|
-42.44 |
Last 97 transactions |
Buy: 13 786 648 | Sell: 31 686 588 |
Tūris Koreliacija
Maravai LifeSciences Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
GRMN | 0.911 |
DINT | 0.905 |
ZBRA | 0.905 |
AQWA | 0.899 |
ULBI | 0.886 |
MMLP | 0.88 |
IESC | 0.878 |
AAXJ | 0.878 |
CTRE | 0.877 |
AIA | 0.877 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
ATOM | -0.875 |
AKAM | -0.872 |
PEV | -0.867 |
FRSH | -0.855 |
SYPR | -0.853 |
OTEX | -0.842 |
VRSN | -0.84 |
IONS | -0.835 |
ENSC | -0.828 |
CVRX | -0.825 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Maravai LifeSciences Koreliacija - Valiuta/Žaliavos
Maravai LifeSciences Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $288.95M |
Bruto pelnas: | $137.60M (47.62 %) |
EPS: | $-0.900 |
FY | 2023 |
Pajamos: | $288.95M |
Bruto pelnas: | $137.60M (47.62 %) |
EPS: | $-0.900 |
FY | 2022 |
Pajamos: | $883.00M |
Bruto pelnas: | $714.04M (80.87 %) |
EPS: | $3.73 |
FY | 2021 |
Pajamos: | $799.24M |
Bruto pelnas: | $658.68M (82.41 %) |
EPS: | $1.590 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Maravai LifeSciences
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.